Pulsus
Publish your manuscript
Journal of Basic and Clinical Pharmacy
Google Scholar citation report
Citations : 14978

Journal of Basic and Clinical Pharmacy received 14978 citations as per google scholar report

Flyer image

Indexed In

Unveiling the Role of IL-6 in Indirect Drug Interactions and Metabolism

Baozu Zhang*
 
Department of Pharmacology, University of Sao Paulo, Sao Paulo, Brazil
 
*Correspondence: Baozu Zhang, Department of Pharmacology, University of Sao Paulo, Sao Paulo, Brazil, Email: zhang136@gmail.com

Received: 29-Mar-2024, Manuscript No. Jbclinphar-24-134418; Editor assigned: 01-Apr-2024, Pre QC No. Jbclinphar-24-134418 (PQ); Reviewed: 15-Apr-2024 QC No. Jbclinphar-24-134418; Revised: 22-Apr-2024, Manuscript No. Jbclinphar-24-134418 (R); Published: 29-Apr-2024

Citation: Zhang B. Unveiling the Role of IL-6 in Indirect Drug Interactions and Metabolism. J Basic Clin Pharma.2024,15(2):348.

This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact reprints@jbclinpharm.org

Description

Interleukin-6 (IL-6), a multifunctional cytokine, plays an important role in modulating various physiological processes, including inflammation, immune response, and hematopoiesis. Beyond its well-established functions, emerging research suggests that IL-6 also exerts significant influence on drug metabolism, particularly through indirect drug interactions. Understanding the complex relationship between IL-6 and drug metabolism is crucial for optimizing therapeutic outcomes and mitigating potential adverse effects in clinical practice. The liver serves as the primary site for drug metabolism, where enzymes such as cytochrome P450 (CYP) isoforms catalyze the biotransformation of xenobiotics into more hydrophilic metabolites for elimination. IL-6, known for its pro-inflammatory properties, has been shown to suppress the activity of various drug-metabolizing enzymes, including CYPs, through complex signaling pathways. This suppression can lead to alterations in drug metabolism kinetics, potentially resulting in reduced efficacy or increased toxicity of co-administered drugs [1].

IL-6 exerts its influence on drug metabolism through multiple mechanisms. One key mechanism involves the activation of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway upon IL-6 binding to its receptor. This pathway regulates the expression of various genes, including those encoding drug-metabolizing enzymes and transporters. IL-6-induced activation of JAK/STAT signaling can lead to alterations in the expression levels and activity of CYP enzymes, thereby impacting drug metabolism. Additionally, IL-6-mediated inflammation can trigger the release of other cytokines and inflammatory mediators, which further contribute to the dysregulation of drug-metabolizing enzymes. Pro-inflammatory cytokines such as Tumor Necrosis Factor-Alpha (TNF-α) and Interleukin-1 Beta (IL-1β) have been shown to interact synergistically with IL-6, exacerbating the suppression of CYP activity and amplifying the potential for drug interactions [2,3].

The impact of IL-6-mediated drug interactions extends to clinical practice, where it poses challenges for healthcare providers in optimizing pharmacotherapy. Patients with conditions characterized by elevated IL-6 levels, such as inflammatory disorders or infections, may be at increased risk of experiencing altered drug metabolism and subsequent therapeutic failure or toxicity. Furthermore, the use of drugs that modulate IL-6 signaling, such as monoclonal antibodies targeting IL-6 receptors, can exacerbate or mitigate IL-6-mediated drug interactions, necessitating careful consideration of co-administered medications. To mitigate IL-6-mediated drug interactions, healthcare providers should adopt a comprehensive approach that takes into account patient-specific factors, including underlying medical conditions, concomitant medications, and genetic variability in drug metabolism enzymes. Close monitoring of therapeutic response and adverse effects is essential, particularly in patients receiving drugs with narrow therapeutic indices or those susceptible to IL-6-mediated alterations in drug metabolism [4].

Further research is needed to examine the precise mechanisms underlying IL-6-mediated drug interactions and their clinical implications. Novel therapeutic strategies targeting IL-6 signaling pathways may offer potential avenues for mitigating drug interactions and optimizing pharmacotherapy in patients with conditions associated with dysregulated IL-6 levels. Additionally, the development of predictive biomarkers for identifying individuals at risk of IL-6- mediated drug interactions could facilitate personalized medicine approaches and improve patient outcomes [5].

IL-6 plays a central role in modulating drug metabolism through indirect interactions, exerting significant influence on the pharmacokinetics of co-administered medications. Understanding the mechanisms underlying IL-6-mediated drug interactions is essential for optimizing therapeutic efficacy and minimizing adverse effects in clinical practice. Future research goals aimed at explaining these mechanisms and developing targeted therapeutic interventions hold promise for enhancing pharmacotherapy outcomes and advancing precision medicine approaches.

References